DKDelphine Kemlin

Delphine Kemlin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Delphine Kemlin has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Arnaud Marchant

    European Plotkin Institute for Vaccinology, Université Libre de Bruxelles, 900 Route de Lennik, 170 Anderlecht, Belgium; ULB Centre for Research in Immunology (U-CRI), Université Libre de Bruxelles, 8 Rue Adrienne Bolland, 6041 Gosselies, Belgium

    4 shared publications
  • Isabelle Desombere

    Laboratory of Immune Response, Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium

    3 shared publications
  • Leo Heyndrickx

    Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

    3 shared publications
  • Nicolas Gemander

    European Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium; Department of Nephrology, Dialysis and Transplantation, Erasme Hospital, Université libre de Bruxelles (ULB), Brussels, Belgium

    3 shared publications
  • Pieter Pannus

    Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium

    3 shared publications
  • Alain Le Moine

    Department of Nephrology, Dialysis and Renal Transplantation, Hôpital Erasme, Université libre de Bruxelles Bruxelles Belgium

    2 shared publications

Latest Publications

  • Open Access

    Persistent defect in SARS-CoV-2 humoral and cellular immunity in lung transplant recipients

    by Isabelle Etienne, Delphine Kemlin, Nicolas Gemander, Véronique Olislagers, Alexandra Waegemans, Emilie Dhondt, Leo Heyndrickx, Stéphanie Depickère, Alexia Charles, Maria Goossens, et al.


  • Open Access

    Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients

    by Delphine Kemlin, Nicolas Gemander, Stéphanie Depickère, Véronique Olislagers, Daphnée Georges, Alexandra Waegemans, Pieter Pannus, Anne Lemy, Maria E. Goossens, Isabelle Desombere, et al.


  • Open Access

    Hybrid immunity to SARS-CoV-2 in kidney transplant recipients and hemodialysis patients

    by Delphine Kemlin, Anne Lemy, Pieter Pannus, Isabelle Desombere, Nicolas Gemander, Maria E. Goossens, Arnaud Marchant, Alain Le Moine


  • Open Access

    Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial

    by Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y Neven, Leo Heyndrickx, Johan Michiels, Elisabeth Willems, Stéphane De Craeye, Antoine Francotte, et al.

    Fractional dosing of COVID-19 vaccines could accelerate vaccination rates in low-income countries. Dose-finding studies of the mRNA vaccine BNT162b2 (Pfizer-BioNTech) suggest that a fractional dose induces comparable antibody responses to the full dose in people 0.67. Primary analysis was done on the per-protocol population, including infection naïve participants only. 145 participants were enrolled and randomized, were mostly female (69.5%), of European origin (95%), with a mean age of 40.4 years (SD 7.9). At 28 days post second dose, the geometric mean titre (GMT) of anti-RBD IgG of the reduced dose regimen (1,705 BAU/mL) was not non-inferior to the full dose regimen (2,387 BAU/mL), with a GMR of 0.714 (two-sided 95% CI 0.540–0.944). No serious adverse events occurred. While non-inferiority of the reduced dose regimen was not demonstrated, the anti-RBD IgG titre was only moderately lower than that of the full dose regimen and, importantly, still markedly higher than the reported antibody response to the licensed adenoviral vector vaccines. These data suggest that reduced doses of the BNT162b2 mRNA vaccine may offer additional benefit as compared to the vaccines currently in use in most low and middle-income countries, warranting larger immunogenicity and effectiveness trials. Trial Registration: The trial is registered at ClinicalTrials.gov (NCT04852861).


  • Open Access

    Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients

    by Delphine Kemlin, Nicolas Gemander, Stephanie Depickere, Veronique Olislagers, Daphnee Georges, Alexandra Waegemans, Pieter Pannus, Anne Lemy, M. E. Goossens, Isabelle Desombere, et al.

    As solid organ recipients are at high risk of severe COVID-19 and respond poorly to primary SARS-CoV-2 mRNA vaccination, they have been prioritized for booster vaccination. However, an immunological correlate of protection has not been identified in this vulnerable population. We conducted a prospective monocentric cohort study of 65 kidney transplant recipients who received three doses of SARS-CoV-2 BNT162b2 mRNA vaccination. Associations between symptomatic breakthrough infection (BTI) and vaccine responses, patient demographic and clinical characteristics were explored. Symptomatic COVID-19 was diagnosed in 32% of kidney transplant recipients during a period of six months after the administration of the third vaccine dose. During this period, SARS-CoV-2 delta and omicron were the dominant variants in the general population. Univariate analyzes identified avidity of SARS-CoV-2 receptor binding domain (RBD) binding IgG, neutralizing antibodies and SARS-CoV-2 S2 domain-specific IFN-γ responses as correlates of protection against BTI. Some demographic and clinical parameters correlated with vaccine responses, but none correlated with the risk of BTI. In multivariate analysis, the risk of BTI was best predicted by neutralizing antibody and S2-specific IFN-γ responses, adjusting for age, graft function and mycophenolate mofetil use. In conclusion, both antibody and T cell responses predict the risk of BTI in kidney transplant recipients who received three doses of SARS-CoV-2 mRNA vaccine. T cell responses may help compensate for the suboptimal antibody response to vaccination in this vulnerable population. One Sentence Summary: Antibody and T cell responses to booster SARS-CoV-2 vaccination predict the risk of symptomatic breakthrough infection in kidney transplant recipients